Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk



Supplementary Material

Figure S1: Contribution of MAPKs on co-treatment-induced growth inhibition in A375 cells. (A) Western bolt analysis of the effects of DSeA and/or TRAIL on the phosphorylation status and the expression level of MAPKs. Cells were preatreated with 20 μ M DSeA for 24 h and then co-treated with 40 ng/ml TRAIL for another 24 h. (B) Effects of SP600125 (JNK inhibitor), SB203580 (p38 MAPK inhibitor) and U0126 (ERE inhibitor) on co-treatment-induced A375 cells growth inhibition. Cells were pretreated with 10 μ M SP600125, SB203580 or U0126 1 h prior to the co-treatment. Cell viability was determined by MTT assay. All data are expressed as means \pm SD of triplicates. Bars with different characters are statistically different at *p* < 0.05 level.



Figure S2: Protective effects of p53 siRNA on co-treatment-induced PTEN overexpression in A375 cells. Cells were pretreated with 50 nmol p53 siRNA for 24 h, and then treated in combination with DSeA and TRAIL.



Figure S3: (A) The expression level of PTEN in the indicated cancer cell lines. The synergistic effects between DSeA and TRAIL in a PTEN-wild type MCF-7 cell line (B) and a panel of three PTEN-mutant human cancer cell lines, including MDA-MB-468 (C), U87 (D), U251 (E). Cells were pretreated with 20 μ M DSeA for 24 h and then expose to 40 ng/ml TRAIL for another 24 h.



Figure S4: Roles of ROS in apoptotic cell death induced by DSeA in A375 cells. Inhibitory effects of NAC and GSH on DSeA-induced accumulation of sub-G1 cell population (A, B), activation of caspase-3 and PARP cleavage (C) in A375 cells. Cells were pretreated with 2.5 mM NAC or GSH for 1 h, and then co-treated with or without 40 μ M DSeA for 24 h. Quantitative analysis of cell cycle distribution and apoptotic cell death were measured by flow cytometric analysis. Caspase activities were measured using synthetic fluorescent substrates for caspase-3. Bars with

different characters are statistically different at p < 0.05 level.



Figure S5: Inhibitory effects of NAC and GSH on co-treatment-induced

accumulation of sub-G1 cell population.



Figure S6: Protective effects of NAC on co-treatment-induced PTEN inactivation and overexpression. Cells were pretreated with or without 2.5 mM NAC for 1 h, and then co-treated with 20 μ M DSeA for 24h, followed by treated with 40 ng/ml TRAIL for another 24 h.